As per the agreement, Altacor will undertake research and development on Proximagen’s 5HT2c programme drug candidate – PRX00933 – in treating glaucoma. The company claims, PRX00933 which is
As per the agreement, UCB has acquired Lectus drug discovery and development programmes targeting ion channels used to treat specific set of Central Nervous System (CNS) indications. UCB
The double-blind, placebo-controlled trial, enrolling 60 US subjects, is designed to assess the pharmacokinetic, pharmacodynamic and safety profile of single escalating doses of CR845 in enteric-coated capsules. Cara
The acquisition is expected to help Tjoapack in its growth strategy. Tjoapack specializes in packaging medicines in a solid dosage form and is known for mass serialisation. By
The financial details of the contract have not been disclosed. OctoPlus provides formulation development and clinical material manufacturing services, besides offering drug delivery technologies to develop controlled release
The system is marketed to companies developing biopharmaceuticals including novel compounds and biosimilars with an emphasis on therapeutic monoclonal antibodies. BioFactura president and CEO Darryl Sampey said the
The double blind, placebo controlled trial will enroll 40 patients with prodromal or mild Alzheimer’s disease to measure physical changes in the brains of patients treated with PBT2
EXC 001 drug, co-developed by Excaliard and Isis Pharmaceuticals, is an antisense oligonucleotide that will hinder the process of fibrosis. As per the deal, Pfizer will provide Excaliard
ABQ Health Partners will monitor and analyze the performance of its Electronic Health Record (EHR) solution with the help of Aternity. Aternity will provide FPI Platform, transforming desktop
Through the initiative, development of a screening program to test tumours for major genetic changes will occur. In addition, it will aid in genetic testing of both patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.